Literature DB >> 18217882

Mortality in multiple sclerosis: a review.

P Ragonese1, P Aridon, G Salemi, M D'Amelio, G Savettieri.   

Abstract

This work was undertaken to evaluate studies on mortality caused by multiple sclerosis (MS), to evaluate if useful inferences can be drawn from survival studies that can be applied to clinical practice. A literature search was carried out to find epidemiological studies on MS prognosis, survival, mortality and causes of death relevant to our aim. The World Health Organization (WHO) reports on worldwide cause-specific mortality were also considered. Studies were evaluated according to the duration of the follow-up study, the year of publication and the methodology used. We evaluated MS survival from a methodological point of view and considered if time trends could be drawn from study results. We conclude that mortality is only slightly higher in MS patients when compared with that in the general population. Mortality is higher particularly for older patients and those with longer disease duration.

Entities:  

Mesh:

Year:  2008        PMID: 18217882     DOI: 10.1111/j.1468-1331.2007.02019.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  26 in total

1.  A formative evaluation of customized pamphlets to promote physical activity and symptom self-management in women with multiple sclerosis.

Authors:  Matthew Plow; Francois Bethoux; Kimloan Mai; Bess Marcus
Journal:  Health Educ Res       Date:  2014-07-02

Review 2.  A systematic review of behavioural techniques used in nutrition and weight loss interventions among adults with mobility-impairing neurological and musculoskeletal conditions.

Authors:  M A Plow; S Moore; M Elaine Husni; J P Kirwan
Journal:  Obes Rev       Date:  2014-09-30       Impact factor: 9.213

3.  Etiologies of chronic anterior uveitis at a tertiary referral center over 35 years.

Authors:  Andrea D Birnbaum; Deborah M Little; Howard H Tessler; Debra A Goldstein
Journal:  Ocul Immunol Inflamm       Date:  2010-11-06       Impact factor: 3.070

4.  CaMKIIα Mediates the Effect of IL-17 To Promote Ongoing Spontaneous and Evoked Pain in Multiple Sclerosis.

Authors:  Xiaoyu Hu; Fang Huang; Zaijie Jim Wang
Journal:  J Neurosci       Date:  2017-11-16       Impact factor: 6.167

5.  Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?

Authors:  Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2012-03       Impact factor: 6.570

6.  Multiple cause of death analysis in multiple sclerosis: A population-based study.

Authors:  Katharine Harding; Feng Zhu; Mohammed Alotaibi; Thomas Duggan; Helen Tremlett; Elaine Kingwell
Journal:  Neurology       Date:  2020-01-13       Impact factor: 9.910

Review 7.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

8.  Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.

Authors:  Natalie A Schwehr; Karen M Kuntz; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter; Mary Butler
Journal:  Drugs Aging       Date:  2020-03       Impact factor: 3.923

9.  Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.

Authors:  Lanting Lu; Hilary Pearce; Chris Roome; James Shearer; Iain A Lang; Ken Stein
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

10.  Behavioral assessment of neuropathic pain, fatigue, and anxiety in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy.

Authors:  Peter M Grace; Lisa C Loram; John P Christianson; Keith A Strand; Johanna G Flyer-Adams; Kathryn R Penzkover; John R Forsayeth; Anne-Marie van Dam; Melissa J Mahoney; Steven F Maier; Raymond A Chavez; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2016-05-14       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.